Abstract:OBJECTIVE:To investigate the expressions of E-cadherin (E-cd) and alpha-catenin (alpha-cat) proteins in benign and malignant prostate tumors, and determine whether they could be used as molecular markers for the prognosis of prostate cancer (PCa). METHODS:We detected the expressions of E-cd and alpha-cat in the prostatic tissues from 45 cases of PCa and 10 cases of benign prostatic hyperplasia (BPH) by immunohistochemical Elivision staining, and analyzed the relationships of E-cd and alpha-cat expressions with the PCa stage, PCa grade, preoperative PSA, results of endocrine therapy and prognosis. RESULTS:The E-cd protein was abnormally expressed in 86.7% of the PCa and 10.0% of the PSA patients, and the E-cd expression was significantly lower in the former than in the latter (P < 0.05). The abnormal expressions of E-cd in the PCa patients with metastasis, non-metastasis, Gleason score < or = 7 and > 7 were 85.0, 87.5, 100.0 and 86.7%, respectively, with no significant between-group differences (P > 0.05), those in the PCa patients with PSA < or = 10 and > 10 microg/L were 40.0 and 97.1%, respectively, significantly higher in the former than in the latter (P < 0.05), and those in the PCa patients with and without response to endocrine therapy were 93.8 and 72.7%, respectively, with no significant differences between the two groups (P > 0.05). The alpha-cat protein was abnormally expressed in 93.3% of the PCa and 30.0% of the BPH patients, respectively, and the alpha-cat expression was significantly lower in the former than in the latter (P < 0.05). The abnormal alpha-cat expressions in the PCa patients with metastasis, non-metastasis, Gleason score > 7 and < or = 7 were 90.0, 100.0, 90.0 and 100.0%, respectively, with no significant between-group differences (P > 0.05), those in the PCa patients with PSA < or = 10 and > 10 microg/L were 40.0 and 94.3%, respectively, significantly higher in the former than in the latter (P < 0.05), and those in the PCa patients with and without response to endocrine therapy were 100.0 and 81.8%, respectively, with no significant differences between the two groups (P > 0.05). CONCLUSION:The expressions of E-cd and alpha-cat are significantly lower in PCa than in BPH, and they are not associated with cancerous metastasis, but negatively correlated with the PSA level in PCa patients.

Expression of Raf Kinase Inhibitor Protein and E-cadherin in Prostate Cancer Tissues

[Expression of Tyrosine Phosphatase Containing C-src Homology SH-2 in Benign Prostate Hyperplasia].

[Expressions of E-cadherin and Beta-Catenin in LNCaP and ARCaP Cell Lines and Their Significance].

[Expressions of E-cadherin and Alpha-Catenin in Benign, Malignant and Metastatic Prostate Tumors].

Expression of SRF, E-cadherin and β-catenin in hepatocellular carcinoma and its clinical significances

[Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer].

E-cadherin Expression in Prostate Cancer and Its Correlation with PSA

Immunohistochemical Detection of Raf Kinase Inhibitor Protein in Normal Cervical Tissue and Cervical Cancer Tissue

Prognostic Significance Of E-Cadherin Expression In Hepatocellular Carcinoma: A Meta-Analysis

Overexpression of Raf-1 Kinase Inhibitor Protein Inhibits Cell Invasion and Migration in Lung Cancer Cells Through Suppressing Epithelial-Mesenchymal Transition.

Expression and Significance of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma:Report of 72 Cases

E-cadherin expression in pancreatic cancer and its clinical significance

[Expression of Ksp-cadherin in Renal Epithelial Neoplasm and Its Clinicopathologic Significance].

Correlation of Expression of Extracellular Signal-Regulated Kinase 5 with Microrna-145 in Prostate Cancer

Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study

Correlation and Significance of N-cadherin and E-cadherin Expression in Rectal Cancer

Expression of P27kip1 and CDKs in Prostate Carcinoma and Benign Prostate Hyperplasia Tissues

Correlation between E‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study

The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study.

Expression and Significance of Ezrin in Prostate Cancer

Clinical Significance of RKIP Mrna Expression in Non-Small Cell Lung Cancer